To read the full article sign up for free or sign in.

Ring Therapeutics expands Singapore footprint with new deals

Nov. 5, 2024

Ring Therapeutics Inc. has joined forces with Singapore’s Agency for Science, Technology, and Research and with the Singapore Eye Research Institute to advance the first new class of viral vectors in more than 50 years, Ring CEO Tuyen Ong told BioWorld.

BioWorld BioWorld Asia Deals and M&A Ocular Gene therapy Protein Asia-Pacific

Today's news in brief

BioWorld

BioWorld briefs for Nov. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Nov. 11, 2025.

UK launches strategy to replace animals in research as scientists voice concern

BioWorld

The U.K. government has published a road map for phasing out animal testing in life sciences research and announced £75 million (US$98.6 million) for work to...

Illustration of magnifying glass inspecting brain

Anchoring, and bootstrapping, psychiatry into the precision medicine era

BioWorld Science

Psychiatry has struggled to enter the precision medicine era. But through a mix of innovations and bootstrapping, progress is coming to the field. Scientists are...

Up the bladder ladder, Engene tweak means phase II bell rung

BioWorld

Engene Holdings Inc.’s protocol amendment to its phase II trial with detalimogene voraplasmid in bladder cancer worked out in a big way, and shares of the firm...